The effects of lamotrigine on alcohol seeking and relapse

Neuropharmacology

Volumn 53, Issue 8, 2007, Pages 951-957

  Vengeliene, Valentina ^a   Heidbreder, Christian A ^b   Spanagel, Rainer ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GSK   (Italy)

Author keywords

Alcohol deprivation effect (ADE); Craving; Cue induced reinstatement of alcohol seeking behaviour; Lamotrigine; Relapse

Indexed keywords

LAMOTRIGINE;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

ALCOHOL DRINKING; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CALCIUM CHANNEL BLOCKERS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CONDITIONING, OPERANT; CUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; ETHANOL; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECURRENCE; SELF ADMINISTRATION; TRIAZINES;

EID: 36348963529     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.09.006     Document Type: Article

References (46)

1. Ahmad S., Fowler L.J., and Whitton P.S. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res. 1029 (2004) 41-47
2. Ahmad S., Fowler L.J., and Whitton P.S. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br. J. Pharmacol. 142 (2004) 136-142
3. Bachteler D., Economidou D., Danysz W., Ciccocioppo R., and Spanagel R. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behaviour in rat. Neuropsychopharmacology 30 (2005) 1104-1110
4. Bäckström P., and Hyytiä P. Ionotropic glutamate receptor antagonists modulate cue-induced reinstatement of ethanol-seeking behaviour. Alcohol Clin. Exp. Res. 28 (2004) 558-565
5. Castel-Branco M.M., Falcao A.C., Figueiredo I.V., and Caramona M.M. Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam. Clin. Pharmacol. 19 (2005) 669-675
6. Ciccocioppo R., Martin-Fardon R., and Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behaviour by drug-associated stimuli in rats. Neuropsychopharmacology 27 (2002) 391-399
7. Egli M. Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?. Addict. Biol. 10 (2005) 309-319
8. Heyser C.J., Schulteis G., Durbin P., and Koob G.F. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18 (1998) 125-133
9. Hölter S.M., Danysz W., and Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur. J. Pharmacol. 314 (1996) R1-R2
10. Hölter S.M., Danysz W., and Spanagel R. The non-competitive NMDA receptor antagonist MRZ 2/579 suppresses the alcohol deprivation effect in long-term alcohol drinking rats and substitutes the alcohol cue in a discrimination task. J. Pharmacol. Exp. Ther. 292 (2000) 545-552
11. Hölter S.M., Engelmann M., Kirschke C., Liebsch G., Landgraf R., and Spanagel R. Long-term ethanol self-administration with repeated withdrawal episodes changes ethanol drinking pattern and increases anxiety during withdrawal in rats. Behav. Pharmacol. 9 (1998) 41-48
12. Johnson B.A. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin. Pharmacother. 5 (2004) 1943-1955
13. Johnson B.A. Serotonergic compounds: clinical data. In: Spanagel R., and Mann K. (Eds). Drugs for Relapse Prevention of Alcoholism (2005), Birkhäuser, Basel 107-116
14. Johnson B.A., Ait-Daoud N., Akhtar F.Z., and Ma J.Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry 61 (2004) 905-912
15. Kalivas P.W., Volkow N., and Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45 (2005) 647-650
16. Kalyoncu A., Mirsal H., Pektas O., Unsalan N., Tan D., and Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?. J. Psychopharmacol. 19 (2005) 301-305
17. Krupitsky E.M., Rudenko A.A., Burakov A.M., Slavina T.Y., Grinenko A.A., Pittman B., Gueorguieva R., Petrakis I.L., Zvartau E.E., and Krystal J.H. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin. Exp. Res. 31 (2007) 604-611
18. Krystal J.H., Petrakis I.L., Mason G., Trevisan L., and D`Souza D.C. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol. Ther. 99 (2003) 79-94
19. Lê A.D., and Funk R. Serotonergic compounds: preclinical data. In: Spanagel R., and Mann K. (Eds). Drugs for Relapse Prevention of Alcoholism (2005), Birkhäuser, Basel 95-106
20. Le A.D., Poulos C.X., Harding S., Watchus J., Juzytsch W., and Shaham Y. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol-seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21 (1999) 435-444
21. Lees G., and Leach M.J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamactil) using primary neurological cultures from rat cortex. Brain Res. 612 (1993) 190-199
22. Liu X., and Weiss F. Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J. Pharmacol. Exp. Ther. 300 (2002) 882-889
23. Malcolm R., Myrick H., Brady K.T., and Ballenger J.C. Update on anticonvulsants for the treatment of alcohol withdrawal. Am. J. Addict. 10 (2001) S16-S23
24. Margolin A., Avants S.K., DePhilippis D., and Kosten T.R. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am. J. Drug Alcohol Abuse 24 (1998) 85-101
25. Mariani J.J., Rosenthal R.N., Tross S., Singh P., and Anand O.P. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am. J. Addict. 15 (2006) 76-84
26. Messenheimer J.A. Lamotrigine. Epilepsia 36 (1995) S87-S94
27. Myrick H., Anton R., Voronin K., Wang W., and Henderson S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin. Exp. Res. 31 (2007) 221-227
28. Overstreet D.H., Rezvani A.H., Cowen M., Chen F., and Lawrence A.J. Modulation of high alcohol drinking in the inbred fawn-hooded (FH/Wjd) rat strain: implications for treatment. Addict. Biol. 11 (2006) 356-373
29. Petri A. New developments in the pharmacotherapy of cocaine abuse. Addict. Biol. 12 (2007) 133-151
30. Rodd-Henricks Z.A., McKinzie D.L., Edmundson V.E., Dagon C.L., Murphy J.M., McBride W.J., Lumeng L., and Li T.K. Effects of 5-HT(3) receptor antagonists on daily alcohol intake under acquisition, maintenance, and relapse conditions in alcohol-preferring (P) rats. Alcohol 21 (2000) 73-85
31. Rubio G., Lopez-Munoz F., and Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 8 (2006) 289-293
32. Rubio G., Ponce G., Jimenez-Arriero M.A., Palomo T., Manzanares J., and Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37 (2004) 37-40
33. Samson H.H. Initiation of ethanol reinforcement using a sucrose-substitution procedure in food- and water-sated rats. Alcohol Clin. Exp. Res. 10 (1986) 436-442
34. Sanchis-Segura C., and Spanagel R. Behavioural assessment of drug-reinforcement and addictive features in rodents: an overview. Addict. Biol. 11 (2006) 2-38
35. Shaham Y., Shalev U., Lu L., De Wit H., and Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl.) 168 (2003) 3-20
36. Spanagel R., Pendyala G., Abarca C., Zghoul T., Sanchis-Segura, Magnone M.C., Lascorz J., Depner M., Holzberg D., Soyka M., Schreiber S., Matsuda F., Lathrop M., Schumann G., and Albrecht U. The circadian clock gene Period2 alters the glutamatergic system and thereby modulates alcohol consumption. Nat. Med. 11 (2005) 35-42
37. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22 (1999) 521-527
38. Spanagel R., and Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol. Sci. 18 (1997) 54-59
39. Tsai G., and Coyle J.T. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu. Rev. Med. 49 (1998) 173-184
40. Vengeliene V., Bachteler D., Danysz W., and Spanagel R. The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology 48 (2005) 822-829
41. Vengeliene V., Leonardi-Essmann F., Perreau-Lenz S., Gebicke-Haerter P., Drescher K., Gross G., and Spanagel R. The D3 receptor plays an essential role in alcohol craving and relapse. FASEB J. 20 (2006) 2223-2233
42. Wang S.J., Sibra T.S., and Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12 (2001) 2255-2258
43. Weiss F. Dopaminergic compounds: preclinical data. In: Spanagel R., and Mann K. (Eds). Drugs for Relapse Prevention of Alcoholism (2005), Birkhäuser, Basel 135-153
44. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr. Opin. Pharmacol. 5 (2005) 9-19
45. Wiesbeck G.A. Dopaminergic compounds: clinical data. In: Spanagel R., and Mann K. (Eds). Drugs for Relapse Prevention of Alcoholism (2005), Birkhäuser, Basel 155-161
46. + channels in rat hippocampal neurones. Pflügers Arch. 430 (1995) 437-446